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Abstract 
Background: Hepatitis C virus (HCV) is common in men who have sex with men (MSM) with 
HIV. The Swiss HCVree Trial targeted a micro-elimination by using a treat and counsel strategy. 
Self-reported condomless anal intercourse with non-steady partners was used as the selection 
criterion for participation in a counselling intervention designed to prevent HCV re-infection. The 
purpose of this study was to assess the ability of this criterion to identify men who engaged in 
other sexual risk behaviours associated with HCV re-infection.  
Methods: Men who disclosed their sexual and drug- use behaviours during the prior six 
months, at study baseline, were included in the current study. Using a descriptive comparative 
study design, we explored self-reported sexual and drug-use risk behaviours, compared the 
odds of reporting each behaviour in men who reported and denied condomless anal intercourse 
with non-steady partners during the prior year and calculated the sensitivity/specificity (95% CI) 
of the screening question in relation to the other at-risk behaviours. 
Results: Seventy-two (61%) of the 118 men meeting eligibity criteria reported condomless anal 
intercourse with non-steady partners during the prior year. Many also engaged in other potential 
HCV transmission risk behaviours, e.g., 52 (44%) had used drugs. In participants disclosing 
drug use, 44 (37%) reported sexualised drug use and 17 (14%) injected drugs. Unadjusted odds 
ratios (95% CI) for two well-known risk behaviours were 2.02 (0.80, 5.62) for fisting and 5.66 
(1.49, 37.12) for injecting drug use. The odds ratio for sexualised drug use - a potential mediator 
for increased sexual risk taking - was 5.90 (2.44, 16.05). Condomless anal intercourse with non-
steady partners showed varying sensitivity in relation to the other risk behaviours examined 
(66.7% - 88.2%). 
Conclusions: Although condomless anal intercourse with non-steady partners was fairly 
sensitive in detecting other HCV relevant risk behaviours, using it as the only screening criterion 
could lead to missing a proportion of HIV-positive men at risk for HCV re-infection due to other 
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behaviours. This work also points to the importance of providing access to behavioral 
interventions addressing other sexual and drug use practices as part of HCV treatment. 
Clinical Trial Number: NCT02785666, 30.05.2016  
 
Keywords (6): HIV; Hepatitis C Virus; Homosexuality; Male; Sexual Behavior; Condoms 
Background 
In men who have sex with men (MSM) living with HIV, co-infection with hepatitis C virus (HCV) 
has become a concern over the last twenty years [1]. An HCV RNA-screening of MSM with HIV 
(n=3722) participating in the Swiss HIV Cohort Study (SHCS) between October 2015 and May 
2016 showed a prevalence of 4.8% (n=177) [2]. People living with an HIV/HCV co-infection 
show faster progression of liver fibrosis compared to people with HCV mono-infection and 
higher risk for liver-related morbidity and mortality [3]. Since the introduction of the new direct 
acting antivirals (DAAs) cure is possible in 95% of the cases, making micro-elimination of HCV a 
realistic target [4]. However, the population of MSM with HIV frequently present with HCV (re-) 
infections and current evidence shows that sexual transmission is one important source of (re-) 
infection [5]. Addressing sexual risk behaviour should become an essential component of HCV 
medical treatment [6]. 
In MSM, several sexual behaviours have been described as potentially risky, for example 
mucosally traumatic sexual behaviours including condomless anal intercourse (CAI), receptive 
fisting, rectal bleeding, anal douching, sharing of sex toys and group sex activities; nasally 
applied drugs; injection drug use and drug use in combination with sex [7-9]. Still, to-date, it 
remains controversial which risk behaviours are the most important ones regarding HCV 
transmission in MSM with HIV, and should subsequently constitute the most important targets 
for preventive efforts [10]. 
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From 2015 to 2017, the Swiss HCVree Trial was conducted as an investigator-initiated substudy 
of the SHCS using a test, treat and counsel strategy with the goal to eliminate HCV in the MSM 
population with HIV [11]. An E-health assisted behavioural counselling intervention with nurses 
as counselors was developed and implemented with the aim to reduce sexual risk taking. MSM 
co-infected with HIV/HCV were asked to participate in the counseling intervention if they reported 
condomless anal intercourse with non-steady partners (nsCAI) the year prior to starting treatment 
[11]. Condomless anal intercourse was the only risk behaviour for which SHCS data was available 
[12] at the time of intervention development. However, its usefulness in selecting participants for 
the additional sexual risk reduction intervention remains questionable given that other sexual and 
drug-using behaviours are also important risk factors for HCV transmission. The current analysis 
was conducted to investigate the usefulness of nsCAI as the selection criterion for the behavioural 
intervention. This can provide important information for further studies. Specifically, the aims of 
this study were to (1) describe sexual and drug-using behaviours participants reported during 
Swiss HCVree study baseline assessment and to compare those behaviours in MSM who did and 
did not report nsCAI during the prior year and to (2) examine the condom-use question’s sensitivity 
and specificity in identifying men who engaged in other HCV relevant risk behaviours and who 
may, therefore, also benefit from risk reduction interventions.  
 
Methods 
A descriptive comparative study design was used to address the objectives and included a 
comprehensive assessment of social, medical and behavioural factors. Data were compared for 
differences between the two groups: those who reported nsCAI and those who denied nsCAI 
during the prior year. 
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Setting and participants 
The Swiss HCVree Trial was implemented within the framework of the SHCS, an ongoing 
multicentre prospective observational study that started in 1988. Its participants have been 
shown to be highly representative of all known people living with HIV(PLWH) in Switzerland, 
[13] and modelling studies estimate that 84% of all MSM with HIV in Switzerland are followed in 
the SHCS [14]. During the Swiss HCVree Trial (2015-2017), all adult men with self-identified 
homosexual or bisexual preferences enrolled in the SHCS (n=3722) were assessed for HCV 
ribonucleic acid (RNA) [2]. One hundered twenty-two (122) were diagnosed with HCV and 
treated with  DAAs in one of eight specialized HIV clinics in Switzerland [11] and all but one 
individual were cured. Among the men treated with DAAs, a positive response to the nsCAI 
question in the SHCS during the prior year was used to select men who were invited to 
participate in the sexual risk reduction intervention performed by nurses.  
Data collection 
The data used in this analysis were retrieved from the SHCS database and the Swiss HCVree 
Trial baseline assessment. Data included sociodemographic characteristics (age, ethnicity/race, 
highest completed educational degree) and medical information about HIV from the SHCS 
database and HCV specific information from the Swiss HCVree Trial. At Swiss HCVree Trial 
baseline, participants were asked to complete a self-reported questionnaire about sexual and 
drug-use behaviours during the previous six months. Table 1 summarizes the data collected. 
Data analysis 
Analyses were conducted using the open source R statistical analysis software (Version 1.0.136 
for Mac OS X). Participants’ characteristics and self-reported at-risk sexual and drug-use 
behaviours were analysed descriptively. Depending on the level of measurement and 
distribution of variables, frequencies, percentages, means and standard deviations (SD), or 
median and interquartile range (IQR) were calculated. Based on the SHCS data, participants 
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were divided into two groups: those who reported no sex with non-steady partners or only 
protected anal intercourse during all sexual encounters during the last 12 months (i.e. without 
nsCAI) and those reporting nsCAI. Baseline characteristics, attitudes and self-efficacy regarding 
condom use were compared in the two nsCAI groups. Chi-square tests were used to compare 
categorical variables and the student’s t-test (for age, which was normally distributed) or Mann-
Whitney U tests (for years since HIV diagnosis and scores on the attitudes toward condom use 
and self-efficacy questionnaires, which were not normally distributed) were utilised to compare 
continuous variables. Odds ratios and their 95% confidence intervals (CI) were calculated to 
examine the association between nsCAI and the other risk behaviours assessed. Multivariable 
logistic regression was conducted to determine if adjusting for age and duration of HCV affected 
the relationship between msCAI and the other risk behaviors. We used a manual stepwise 
backward elimination. MedCalc online software 
(https://www.medcalc.org/calc/diagnostic_test.php) was used to calculate the sensitivity and 
specificity (including 95% confidence intervals (CI)) of the condom use screening question with 
non-steady sexual partners in relation to the other at-risk sexual and drug use behaviours. 
 
Results 
During the Swiss HCVree Trial baseline assessment, 118 of 122 participants disclosed their 
sexual and drug-use behaviours and were included in the current study, see Figure 1.  
Based on SHCS data, 72 (61%) MSM reported nsCAI and 46 (39%) reported no nsCAI during 
the 12 months prior to enrollment in the HVCree Trial. There were no significant differences in 
the two groups’ socio-demographic characteristics. There were significant group differences in 
the years since HCV diagnosis; MSM with nsCAI had a shorter median duration of 1.9 years 
(0.9-5.1) compared to MSM without nsCAI with a median duration of 4.8 years (2.1-10.3). 
Participants without nsCAI scored significantly more positive attitudes toward condom use and 
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had higher self-efficacy related to condom use than men with nsCAI (median score=44.00 vs.  
39.00, p=.023 and median score=40.72 vs. 29.23, p<.001 respectively). 
Many men reported engaging in a variety of sexual or drug-use behaviours identified as risk 
factors for HCV-infection: 25 (24%) shared sextoys, 28 (25%) practised fisting and 52 (44%) 
used drugs during the prior six months. In participants who answered the drug-use questions, 
44 (37%) reported sexualised drug use and 17 (15%) injected drugs. Participants reported using 
the following drugs: 30 (26%) used γ-butyrolactone/γ-hydroxybutyric acid (GHB/GBL), 26 (22%) 
cocaine, 22 (19%) crystal methamphetamine, 11 (9%) ketamine and 10 (9%) mephedrone 
(Table 2). Those with nsCAI during the 12 months prior to treatment were more likely to have 
engaged in other risky sexual behaviours than those without nsCAI although the odds in the two 
groups were only statistically significant for drug use, drug use during sex and injecting drugs. 
Adjusting for age and/or HCV duration did not change the relationship between nsCAI and the 
other risk behaviours examined in terms of the direction or significance of the odds ratios.  
Odds ratios for two sexual behaviours with established transmission risk were 2.02 (0.80, 5.62) 
for fisting and 5.66 (1.49, 37.12) for injecting drug use. Sexualised drug use, a potential 
mediator for increasing other risk behaviours, showed an odds ratio of 5.90 (2.44, 16.05), see 
Table 2. 
Table 3 summarizes the results of analyses examining the sensitivity and specificity of reporting 
consistent condom-use with non-steady partners at study baseline in identifying men who did 
not engage in the other at-risk behaviours examined. The nsCAI question had the highest 
sensitivity in relation to the question about injecting drugs (88.2%) and lowest for sharing sex 
toys (66.67%). Specificity was low in all analysed risk behaviours (41.18%-57.58%). 
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Table 3. Sensitivity analysis of screening question “nsCAI” to identify other probable risk 
behaviours for HCV re-infection 
Risk Behaviours Sensitivity† (%) (95% CI)  Specificity‡ (%) (95% CI) 
Any drug use  84.62 (71.92-93.12) 57.58 (44.79-69.66) 
Sexualised drug use  84.09 (69.93-93.36) 52.70 (40.75-64.43) 
Injecting drug use 88.24 (63.56-98.54) 43.56 (33.72-53.80) 
Fisting 75.00 (55.13-89.31) 43.18 (32.66-54.18) 
Sharing of sex toys 66.67 (48.17-82.04) 41.18 (30.61-52.38) 
†The probability that HIV-positive MSM report a selected risk behaviour will also report nsCAI 
‡The probability that HIV-positive MSM will deny nsCAI if they are not engaging in other  selected other 
risk behaviours  
 
Discussion 
The MSM co-infected with HIV/HCV in this study practiced various sexual and drug use 
behaviours associated with HCV transmission risk in addition to condomless sex. While nsCAI 
was associated with higher odds of engaging in other behaviours, based on our findings, relying 
only on this question to identify men at risk for HCV re-infection is likely miss a proportion of 
MSM with HIV at risk for HCV due to other behaviours. Between 16% to 18% of the men who 
denied nsCAI reported engaging in other behaviors that have been associated with an 
increased risk of HCV re-infection. Eighteen percent (18%) of those who denied nsCAI reported 
using drugs. This is an important finding as drug use is seen as a potential mediator for 
increased sexual risk-taking [15, 16].  
Condom use was the only risk behaviour available for all men in the SHCS and was for this 
reason used as the criterion for selecting men to participate in the sexual risk reduction 
behavioural intervention portion of the Swiss HCVree Trial [17]. Despite our use of this inclusion 
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criterion, its discriminatory value in identifying men at high risk for HCV re-infection was unclear. 
However, a recent study from London found that CAI was a significant risk factor for acute HCV 
infection in MSM and in one third of participants it was the only risk factor [9]. In contrast to our 
study, MSM received care in a sexual health clinic and benefitted from a multi-disciplinary 
prevention approach including harm reduction services whereas in our study, HCV treatment 
was given in specialised medical HIV clinics. In line with other investigations in MSM with HIV, 
study participants reported various behaviours other than nsCAI that potentially increased their 
risk of HCV sexual transmission [9]. It has been well documented that condoms are less 
attractive in the MSM community – largely due to the common understanding and awareness 
that HIV treatment is preventive in terms of HIV transmission [18]. Decreasing trends of condom 
use was confirmed in a systematic review of studies across high-income countries [19]. 
Champenois et al. [20] reported that for MSM with HIV the main reasons for not using condoms 
were serosorting and being on antiretroviral therapy (ART) with undetectable viral loads. While 
these traditional HIV-related risk reduction strategies (serosorting and effective HIV treatment) 
have been shown to prevent the transmission of HIV, they have little or no effect in preventing 
HCV or other sexually transmitted diseases.  
In our study, MSM with HIV and nsCAI were more likely to engage in other risk behaviours 
compared to those without nsCAI but the relationship was only statistically significant for drug-
use and sexualized drug-use. However, due to the small sample size, our study was probably 
only adequately powered to detect large differences in the groups. They were two-times more 
likely to practice fisting and six times more likely to report sexualised drug use. The sensitivity of 
the nsCAI question was 85% in relation to drug use. Nevertheless, our findings indicate that 
using nsCAI as the only risk behaviour criterion to select men for the behavioural intervention 
was likely to have resulted in failure to include between 12% and 34% of those engaging in 
other risk behaviours. Each single behaviour included in the current analysis carries a specific 
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HCV transmission risk; however, which behaviour or combinations of behaviours carry the 
highest risks is currently less clear and cannot be answered with this study design.  
Our results are in line with other studies showing associations between higher rates of drug 
use/sexualised drug use and risk behaviors [16, 21, 22]. A substantial proportion of our 
participants reported drug use (44%). Among the men who anwsered these questions (116 for 
sexualized drug use and 117 for injecting drugs), 38% reported sexualised drug use and 15% 
reported injecting substances. In comparison, in two earlier studies on MSM  with HIV– one 
from Madrid (n=742) [21] and one from England/Wales (n=392) [22] 29.1% – 29.5% of 
participants indicated sexualised drug use and 10.1% – 16% injecting drug use. Our group’s 
higher rate of sexualised drug use might reflect differences in the study population, especially 
the fact that our sample’s MSM with HIV were all co-infected with HCV. Several studies have 
found elevated rates of sexualised drug use in MSM co-infected with HIV/HCV, affirming 
associations between sexual HCV transmission and higher risk taking behaviours when using 
substances [23, 24]. Another possible explanation for our group’s high rates of sexualised drug 
use may be related to the study setting: most of our participants were recruited at the centres in 
Zurich, a town known for a comparably high prevalence of sexualised drug use. In the European 
MSM Internet Survey (EMIS-2010), which compared 44 European cities in relation to illicit drug 
use in MSM, place of residence was the strongest predictor. Zurich reported a 7% prevalence of 
using one of the four drugs typically used during sex, ranking sixth of the 44 cities studied, just 
after UK and Spanish cities [8]. In another European survey conducted among MSM in 13 cities, 
overall prevalence of sex associated with drug use was 11.8% (when measured at the last 
sexual encounter), and was more frequently reported by MSM with HIV [25]. 
The four substances typically used during sex were all reported in our study, with GBL/GHB 
being the most common (25%), followed by crystal methamphetamine (19%). In EMIS 
(European MSM Internet Survey), percentages of GBL/GHB use were quite similar, but crystal 
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methamphetamine use was lower [8] than in our study, suggesting a surge in its popularity in 
MSM with HIV. The frequency of cocaine use was also high (22%) – comparable to rates 
reported in the UK ASTRA trial in MSM with HIV or for Zurich in EMIS [8, 16]. To date, few 
studies investigating sexualized drug use have included cocaine. However, our results indicate 
that cocaine may be more common (19%) in sexual contexts than expected.  
This study has several limitations. The study’s cross-sectional design precluded any causal 
inferences about the associations between nsCAI and other behaviours risky for HCV re-
infection. During analysis, we identified some limitations in the formulation of questions, e.g., we 
did not ask about the distinction between insertive or receptive fisting. While self-report 
questionnaire data may be biased, especially for such sensitive domains as sexual and drug 
use behaviour, it is often perceived as superior compared to being asked by someone else 
because of reduced social desirability bias [26]. Given the limited number of MSM co-infected 
with HIV/HCV in Switzerland, the study sample (118 participants) was small. The small sample 
size may have limited our ability to detect statistically significant differences in behaviors in the 
nsCAI and non-nsCAI groups that were clinically meaningful. One strength of the study is that 
the Swiss HCVree Trial (the source of data for this study) screened and treated all participants 
co-infected with HCV in the SHCS, so the sample is likely to be representative of MSM with HIV 
living in Switzerland [13].  
 
Conclusions  
Our findings support existing research that MSM co-infected with HIV/HCV engage in various 
sexual and drug-use behaviours, potentially increasing their risk of HCV re-infection. Men who 
reported using condoms inconsistently with non-steady partners were more likely to report 
engaging in the other sexual and drug-use behaviors measured although the differences were 
only statistically significant for the drug-use behaviors. nsCAI was fairly sensitive in identifying 
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men who also engaged in other risk behaviours, but relying only on it to identify men at risk for 
HCV infection would miss a proportion of MSM with HIV practicing other potentially modifiable 
behaviours. Based on our findings we recommend comprehensive screening of potential risk 
behaviours to identify men whose sexual and drug use behaviors increase their risk for HCV 
infection. We recommend offering all MSM co-infected with HIV/HCV behavioural interventions 
designed to reduce sexual and drug use risk behaviours.  
 
 
List of abbreviations 
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SD  Standard deviation  
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Table 1. Data collected 
Database Domain 
Variables assessed 
Question Answer 
SHCS, 
reported in 
interview 
situation 
Screening question 
Selection criteria for 
sexual risk reduction 
intervention 
 
“Over the last 12 months, did 
you have unprotected anal 
intercourse with occasional 
partners?” 
Yes/no 
 
Swiss HCVree 
Trial, 
Self-completed 
questionnaires 
Sociodemographic 
Partnership 
 
“Did you have a stable 
partnership in the last 6 
months?” 
 
Yes/no 
 Risk Behaviours 
Sextoys 
 
“Over the last 6 months, did you 
use sextoys with non-steady 
partners? 
 
Yes/no 
 Fisting “Over the last 6 months, did you 
practice fisting?” 
Yes/no 
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 Drug use “Did you use one or more of the 
following substances in the last 
6 months?” 
Cocaine 
γ-butyrolactone/γ-
hydroxybutyric acid (GHB/GBL) 
crystal methamphetamine (CM) 
ketamine 
mephedrone 
 
 
 
 
 
Yes/no 
Yes/no 
 
Yes/no 
Yes/no 
Yes/no 
 
 
  “If your answer is yes, how did 
you take the substance(s)?” 
injection (slammed)/ 
intranasal/orally/smoked/ 
mucosally (anal) 
 Sexualised drug use “If your answer is yes, did you 
take any of the above-
mentioned substance(s) in 
combination with sex?” 
Yes/no 
 
 Psychological 
constructs 
Attitudes towards 
condom use 
 
 
Sexual risks scale-attitudes 
toward condom use [27] 13 
items rated on a 5-point Likert 
scale 
 
 
 
1 (I don’t agree at all) to 5 
(I completely agree). 
Possible scores range 
from 13 to 65 
20 
 
 Condom self-efficacy Self-efficacy for negotiating 
condom use [28], 5 items rated 
on a 1–10 scale 
0 (I cannot) to 10 (I am 
sure that I can). Possible 
scores range from 0 to 50 
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Table 2. Sociodemographic and HCV-related risk behaviours in the last 6 months at study baseline  
 
Sociodemographic and 
HCV-related risk 
behaviours at study 
baseline 
Total 
 
(n=118) 
Participants 
without nsCAI 
(n=46) 
Participants 
with nsCAI  
(n=72) 
Univariable 
Odds Ratio 
(95% CI) 
Multivariable 
Adjusted OR  
(95% CI) 
for age and HCV 
duration 
 
Adjusted OR  
(95% CI) 
for HCV duration 
Age, mean (sd) 46.6 (+/- 9.2) 
 
49.0 (+/- 9.1) 45.1  
(+/- 9.1) 
0.64 (0.41, 0.96)1   
HCV duration, median (IQR) 2.9 (1.1-7.1) 4.8 (2.1-10.3) 1.9 (0.9-5.1) 0.87 (0.80, 0.94)   
Sharing sextoys, n (%) 
(n=104/38/66)2 
25 (24) 7 (18) 18 (28) 1.53 (0.58, 4.40) 1.05 (0.36, 3.21) 1.08 (0.37, 3.29) 
Fisting, n (%) (n=114/43/71)2 28 (25) 7 (16) 21 (30) 2.02 (0.80, 5.62) 2.12 (0.78, 6.31) 1.92 (0.72, 5.60) 
Drug use, n (%) 
(n=117/45/72)2 
GHB/GBL, n (%) 
Cocaine ,n (%) 
 
 
52 (44) 
 
30 (26) 
26 (22) 
 
 
8 (18) 
 
3 (7) 
6 (13) 
 
 
44 (61) 
 
27 (38) 
20 (28) 
 
 
7.27 (3.08, 18.91) 
 
8.60 (2.78, 37.87) 
2.56 (0.99, 7.55) 
 
5.58 (2.26, 15.02) 
 
6.64 (2.04, 30.18) 
2.36 (0.85,  7.39) 
 
5.79 (2.37, 15.42) 
 
6.91 (2.15, 31.07) 
2.49 (0.91, 7.6) 
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Crystal methamphetamine,  
n %) 
Ketamine, n (%) 
Mephedrone, n (%) 
Use of any of the drugs 
listed above during sex, n 
(%) (n=116/45/71)2 
Reporting injection of drugs, 
n (%) (n=117/45/72)2 
22 (19) 
 
11 (9) 
10 (9) 
44 (38) 
 
 
17 (15) 
1 (2) 
 
2 (4) 
- 
7 (16) 
 
 
2 (4) 
21 (29) 
 
9 (14) 
10 (15) 
37 (52) 
 
 
15 (21) 
18.48 (3.63, 
338.0) 
3.12 (0.76, 21.14) 
 
5.90 (2.44, 16.05) 
 
 
5.66 (1.49, 37.12) 
15.47 (2.89, 
288.31) 
3.55 (7.82, 25.71) 
 
4.42 (1.73, 12.52) 
 
 
4.45 (1.10, 30.15) 
15.91 (3.01, 
294.78) 
3.55 (7.82, 25.71) 
 
4.63 (1.84, 12.92) 
 
 
4.53 (1.13, 30.51) 
 
1 Unit 10 years 
2 specified how many HIV-positive MSM answered the question (n=total group/without nsCAI/with nsCAI) 
 
 
 
FIGURE  
Figure 1 Title: Flowchart Swiss HCVree Trial and group building according to men’s response to the nsCAI screening question
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